SPHK1 and cancer: Our study found that, stimulation of A549 cancer cells with IGF-1 induced overexpression and activation of SphK1, decreased E-cadherin expression and increased expression of N-Cadherin, vimentin and fibronectin, which were dependent on SphK1 activity, while SKI-II, the specific inhibitor of SphK1, could suppress the above effects.